Show simple item record

dc.contributor.authorRicklin, Daniel
dc.contributor.authorBarratt-Due, Andreas
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2018-04-13T07:36:05Z
dc.date.available2018-04-13T07:36:05Z
dc.date.issued2017-05-31
dc.description.abstractResearch during past decades made it evident that complement is involved in more tasks than fighting infections, but has important roles in other immune surveillance and housekeeping functions. If the balance between complement activation and regulation is out of tune, however, complement can quickly turn against the host and contribute to adverse processes that result in various clinical conditions. Whereas clinical awareness was initially focused on complement deficiencies, excessive activation and insufficient regulation are frequently the dominant factors in complement-related disorders. The individual complement profile of a patient often determines the course and severity of the disease, and the pathophysiological involvement of complement may be highly diverse. As a consequence, complement assays have evolved as essential tools not only in initial diagnosis but also for following disease progression and for monitoring complement-targeted therapies, which become increasingly available in routine clinical use. We herein review the current state of complement-directed drug candidates in clinical evaluation and provide an overview of extended indications considered for the FDAapproved inhibitor eculizumab. Furthermore we review the literature describing cases reports and case series where eculizumab has been used “off-label”. Finally, we give a summary of the currently available tests to measure complement profiles and discuss their suitability in diagnostics and treatment monitoring. With complement finally entering the clinical arena, there are intriguing opportunities for treating complementmediated diseases. However, this progress also requires a new awareness about complement pathophysiology, adequate diagnostic tools and suitable treatment options among clinicians treating patients with such disorders.en_US
dc.descriptionAccepted manuscript version, licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0. </a>" Published version available in <a href=http://doi.org/10.1016/j.molimm.2017.05.013> Molecular Immunology (2017), 89, 10-21. </a>en_US
dc.identifier.citationRicklin, D., Barratt-Due, A. & Mollnes, T. E. (2017). Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Molecular Immunology, 89, 10-21. http://doi.org/10.1016/j.molimm.2017.05.013en_US
dc.identifier.cristinIDFRIDAID 1513501
dc.identifier.doi10.1016/j.molimm.2017.05.013
dc.identifier.issn0161-5890
dc.identifier.issn1872-9142
dc.identifier.urihttps://hdl.handle.net/10037/12520
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalMolecular Immunology
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical immunology: 716en_US
dc.titleComplement in clinical medicine: Clinical trials, case reports and therapy monitoringen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record